To Exam the Effects of Phyllanthus Niruri Extracts on Human Neutrophils

To Exam the Effects of Phyllanthus Niruri Extracts (Corilagin, Phyllanthin and Brevifolin) on Human Neutrophils

To exam the effects of Phyllanthus niruri extracts(corilagin, phyllanthin and brevifolin) on human neutrophils

Study Overview

• Status: Completed
• Conditions: Neutrophil; Phyllanthus Abnormis Poisoning
• Intervention / Treatment: Procedure: venipuncture

Detailed Description

Phyllanthus niruri extracts have anti-inflammatory effects in various cellular systems (monocytes, neutrophil). However, the underlying effects and mechanisms of Phyllanthus niruri extracts on neutrophils have not yet been investigated in detail.

In this study, first we would like to systemic exam the effects of corilagin, phyllanthin and brevifolin, three major active components, on human neutrophils.

Further to clarify whether Phyllanthus niruri extracts have any effect on neutrophils that may provide some insights on the ability of these compounds to modulate the innate immune response in acute organ injury.

• Study Type: Observational
• Enrollment (Actual): 240

Contacts and Locations

Study Locations

• Taiwan
  • Taoyuan, Taiwan, 333
    • Chang Gung Memorial Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 35 years (Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Voluntary healthy donor (20-35 years old) do not have coagulopathy, systemic infective disease and severe liver and renal function impairment.

Description

Inclusion Criteria:

• Healthy volunteers who aged 20-35 years.
• Do not have coagulopathy, systemic infection disease and severe liver and renal function impairment
• Accept venipuncture

Exclusion Criteria:

• Healthy volunteers who aged over 35 years.
• Have coagulopathy, systemic infection disease and severe liver and renal function impairment

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Measurement of superoxide anion release	Superoxide anion released from human neutrophils were determined by measuring ferricytochrome c reduction.The neutrophils were activated with fMLF (30 nM) and cytochalasin B(0.5 μg/mL) (fMLF/CB). Changes in absorbance that occurred at 550 nm were observed continuously using a double beam spectrophotometer. Superoxide anion level was calculated using the methods described in previous report.	After neutrophil isolation, an average of 3 months
Measurement of intracellular ROS formation	Neutrophil ROS production was determined from the conversion of non-fluorescent DHR 123 to fluorescent rhodamine 123, detected using flow cytometry. Neutrophils (2 × 106 cells/ml) were incubated with DHR 123 (2 μM) for 15 min at 37°C, and then treated with honokiol (0.1-10 μM) for 5 min before the addition of fMLP/CB (0.5 μg/ml) for a further 5 min. The change in fluorescence was analysed using flow cytometry	After neutrophil isolation, an average of 3 months

Collaborators and Investigators

• Sponsor: Chang Gung Memorial Hospital

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2022
• Primary Completion (Actual): September 30, 2022
• Study Completion (Actual): July 31, 2023

Study Registration Dates

• First Submitted: January 23, 2022
• First Submitted That Met QC Criteria: January 23, 2022
• First Posted (Actual): January 25, 2022

Study Record Updates

• Last Update Posted (Actual): September 1, 2023
• Last Update Submitted That Met QC Criteria: August 31, 2023
• Last Verified: January 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Chemically-Induced Disorders; Poisoning
• Other Study ID Numbers: 202002189B0

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No